Abivax SA (ABVX) on Tuesday launched an underwritten public offering of approximately $600 million of its American Depositary Shares, with an option for underwriters to purchase up to an additional 15% of the offered shares.
Proceeds will be used primarily to fund potential commercialization of lead drug candidate obefazimod in the United States, clinical research and development for ulcerative colitis and Crohn's disease, and general corporate purposes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.